128 related articles for article (PubMed ID: 15388473)
21. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
22. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
[TBL] [Abstract][Full Text] [Related]
23. [Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci].
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López F; Gómez M;
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):13-6. PubMed ID: 19406529
[TBL] [Abstract][Full Text] [Related]
24. Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance.
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López-Fabal F; Gómez M;
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):373-9. PubMed ID: 21683269
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
Appleman MD; Citron DM
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
[TBL] [Abstract][Full Text] [Related]
26. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
27. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection.
Rouse MS; Steckelberg JM; Patel R
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):363-5. PubMed ID: 17449212
[TBL] [Abstract][Full Text] [Related]
29. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
Mendes RE; Sader HS; Jones RN
Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
[TBL] [Abstract][Full Text] [Related]
30. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
Sader HS; Becker HK; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
[TBL] [Abstract][Full Text] [Related]
32. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.
Hoellman DB; Lin G; Ednie LM; Rattan A; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2003 Mar; 47(3):1148-50. PubMed ID: 12604559
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients.
Kratzer C; Rabitsch W; Hirschl AM; Graninger W; Presterl E
Eur J Haematol; 2007 Nov; 79(5):405-9. PubMed ID: 17714506
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of the new quinolone WCK 771 against staphylococci.
Jacobs MR; Bajaksouzian S; Windau A; Appelbaum PC; Patel MV; Gupte SV; Bhagwat SS; De Souza NJ; Khorakiwala HF
Antimicrob Agents Chemother; 2004 Sep; 48(9):3338-42. PubMed ID: 15328094
[TBL] [Abstract][Full Text] [Related]
35. Compensatory mutations in agrC partly restore fitness in vitro to peptide deformylase inhibitor-resistant Staphylococcus aureus.
Zorzet A; Andersen JM; Nilsson AI; Møller NF; Andersson DI
J Antimicrob Chemother; 2012 Aug; 67(8):1835-42. PubMed ID: 22577101
[TBL] [Abstract][Full Text] [Related]
36. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
Bogdanovich T; Ednie LM; Shapiro S; Appelbaum PC
Antimicrob Agents Chemother; 2005 Oct; 49(10):4210-9. PubMed ID: 16189100
[TBL] [Abstract][Full Text] [Related]
37. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Micek ST
Clin Infect Dis; 2007 Sep; 45 Suppl 3():S184-90. PubMed ID: 17712745
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
39. Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers.
Picazo JJ; Betriu C; Culebras E; Rodríguez-Avial I; Gómez M; López F;
Diagn Microbiol Infect Dis; 2009 Aug; 64(4):448-51. PubMed ID: 19631100
[TBL] [Abstract][Full Text] [Related]
40. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
